Related Experiment Video

Updated: Aug 13, 2026

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

Selectively replicating adenoviruses for cancer therapy: an update on clinical development

Leonard E Post1

  • 1Onyx Pharmaceuticals Inc, 3031 Research Drive, Richmond, CA 94806, USA. lpost@onyx-pharm.com

Current Opinion in Investigational Drugs (London, England : 2000)
|January 17, 2003
PubMed

Insights

Engineered adenoviruses selectively target cancer cells lacking the p53 pathway, demonstrating safety and encouraging anticancer activity in clinical trials. Future developments aim to enhance replication and gene therapy applications for metastatic cancer treatment.

Area of Science:

  • Oncolytic virotherapy
  • Gene therapy
  • Cancer research

Background:

  • Adenoviruses can be modified for selective replication in tumor cells.
  • ONYX-015, a p53-deficient replicating adenovirus, was the first to enter clinical trials.
  • Established safety profile for selectively replicating adenoviruses in over 300 cancer patients.

Purpose of the Study:

  • To review the clinical development and potential of selectively replicating adenoviruses.
  • To highlight advancements in oncolytic adenovirus technology.
  • To explore future directions for metastatic cancer therapy.

Main Methods:

  • Clinical trials of ONYX-015 and other selectively replicating adenoviruses.
  • Investigation of adenoviruses engineered for tumor-specific replication.
  • Development of adenoviral vectors for gene therapy applications.

Main Results:

  • ONYX-015 demonstrated safety and encouraging anticancer activity in clinical trials.
  • First clinical trial of a transgene-carrying, selectively replicating adenovirus reported.
  • Established safety of oncolytic adenoviruses in a large patient cohort.

Conclusions:

  • Selectively replicating adenoviruses are a safe and promising approach for cancer therapy.
  • Ongoing research focuses on improving viral replication efficiency and gene delivery.
  • Adenoviral vectors hold potential for systemic therapy of metastatic cancers.

More Related Videos

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...